$1bn Amunix Buy Brings Sanofi Next-Generation TCE Platform
Masking Technology Could Address Safety Limitations Of Solid Tumor Candidates
Executive Summary
The deal bolsters Sanofi’s immuno-oncology pipeline and marks its sixth acquisition this year.